Advertisement

Proton pump inhibitors and risk for recurrent ischemic events or death in outpatients with symptomatic artery disease

      Highlights

      • The influence of proton pump inhibitors (PPIs) on outcome in patients with symptomatic artery disease remains controversial.
      • Patients using PPIs were at a lower risk for subsequent ischemic event but at a higher risk for death.
      • These results fuel the controversy over the influence of PPIs on cardiovascular risk and mortality.

      Abstract

      Bagkground and aims

      The influence of proton pump inhibitors (PPIs) on outcome in patients with symptomatic artery disease remains controversial.

      Methods

      FRENA is a prospective registry of consecutive outpatients with symptomatic coronary (CAD), cerebrovascular (CVD) or peripheral artery disease (PAD). We compared the risk for subsequent ischemic events or death according to the use of PPIs.

      Results

      As of December 2016, 5170 patients were recruited: 1793 (35%) had CAD, 1530 (30%) CVD and 1847 (35%) had PAD. Overall, 2289 patients (44%) were regularly using PPIs. During a median follow-up of 36 months, 172 patients suffered a recurrent myocardial infarction, 139 had ischemic stroke, 71 underwent limb amputation and 267 died (cardiovascular death, 109). On multivariable analysis, patients using PPIs were at a lower risk for subsequent limb amputation (hazard ratio [HR]: 0.53; 95%CI: 0.30–0.94), a similar risk for myocardial infarction (HR: 0.78; 95%CI: 0.55–1.10) or stroke (HR: 0.93; 95%CI: 0.64–1.35) and at a higher risk of death (HR: 1.37; 95%CI: 1.04–1.79).

      Conclusions

      Among stable outpatients with symptomatic artery disease, the use of PPIs was associated with a lower risk for subsequent ischemic events but a higher risk for death.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Freedberg D.E.
        • Kim L.S.
        • Yang Y.-X.
        The risks and benefits of long-term use of proton pump inhibitors: expert Review and best practice advice from the American gastroenterological association.
        Gastroenterology. 2017; 152: 706-715https://doi.org/10.1053/j.gastro.2017.01.031
        • Schnoll-Sussman F.
        • Katz P.O.
        Clinical implications of emerging data on the safety of proton pump inhibitors.
        Curr. Treat. Options Gastroenterol. 2017; 15: 1-9https://doi.org/10.1007/s11938-017-0115-5
        • Juurlink D.N.
        Proton pump inhibitors and clopidogrel: putting the interaction in perspective.
        Circulation. 2009; 120: 2310-2312https://doi.org/10.1161/CIRCULATIONAHA.109.907295
        • Juurlink D.N.
        • Gomes T.
        • Ko D.T.
        • Szmitko P.E.
        • Austin P.C.
        • Tu J.V.
        • Henry D.A.
        • Kopp A.
        • Mamdani M.M.
        A population-based study of the drug interaction between proton pump inhibitors and clopidogrel.
        CMAJ (Can. Med. Assoc. J.). 2009; 180: 713-718https://doi.org/10.1503/cmaj.082001
        • Munoz-Torrero J.F.S.
        • Escudero D.
        • Suarez C.
        • Sanclemente C.
        • Pascual M.T.
        • Zamorano J.
        • Trujillo-Santos J.
        • Monreal M.
        Concomitant use of proton pump inhibitors and clopidogrel in patients with coronary, cerebrovascular, or peripheral artery disease in the factores de Riesgo y ENfermedad Arterial (FRENA) registry.
        J. Cardiovasc. Pharmacol. 2011; 57: 13-19https://doi.org/10.1097/FJC.0b013e3181fc65e5
        • European Medicine Agency
        Public statement: interaction between clopidogrel and proton pump inhibitors.
        • FDA
        FDA Reminder to Avoid Concomitant Use of Plavix (Clopidogrel) and Omeprazole.
        2009
        • Katz P.O.
        • Gerson L.B.
        • Vela M.F.
        Guidelines for the diagnosis and management of gastroesophageal reflux disease.
        Am. J. Gastroenterol. 2013; 108 (308–28; quiz 329)https://doi.org/10.1038/ajg.2012.444
        • Charlot M.
        • Grove E.L.
        • Hansen P.R.
        • Olesen J.B.
        • Ahlehoff O.
        • Selmer C.
        • Lindhardsen J.
        • Madsen J.K.
        • Kober L.
        • Torp-Pedersen C.
        • Gislason G.H.
        Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study.
        BMJ. 2011; 342: d2690https://doi.org/10.1136/bmj.d2690
        • Charlot M.
        • Ahlehoff O.
        • Norgaard M.L.
        • Jorgensen C.H.
        • Sorensen R.
        • Abildstrom S.Z.
        • Hansen P.R.
        • Madsen J.K.
        • Kober L.
        • Torp-Pedersen C.
        • Gislason G.
        Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study.
        Ann. Intern. Med. 2010; 153: 378-386https://doi.org/10.7326/0003-4819-153-6-201009210-00005
        • Casula M.
        • Scotti L.
        • Galimberti F.
        • Mozzanica F.
        • Tragni E.
        • Corrao G.
        • Catapano A.L.
        Use of proton pump inhibitors and risk of ischemic events in the general population.
        Atherosclerosis. 2018; 277: 123-129https://doi.org/10.1016/j.atherosclerosis.2018.08.035
        • Moayyedi P.
        • Eikelboom J.W.
        • Bosch J.
        • Connolly S.J.
        • Dyal L.
        • Shestakovska O.
        • Leong D.
        • Anand S.S.
        • Stork S.
        • Branch K.R.H.
        • Bhatt D.L.
        • Verhamme P.B.
        • O'Donnell M.
        • Maggioni A.P.
        • Lonn E.M.
        • Piegas L.S.
        • Ertl G.
        • Keltai M.
        • Bruns N.C.
        • Muehlhofer E.
        • Dagenais G.R.
        • Kim J.-H.
        • Hori M.
        • Steg P.G.
        • Hart R.G.
        • Diaz R.
        • Alings M.
        • Widimsky P.
        • Avezum A.
        • Probstfield J.
        • Zhu J.
        • Liang Y.
        • Lopez-Jaramillo P.
        • Kakkar A.K.
        • Parkhomenko A.N.
        • Ryden L.
        • Pogosova N.
        • Dans A.L.
        • Lanas F.
        • Commerford P.J.
        • Torp-Pedersen C.
        • Guzik T.J.
        • Vinereanu D.
        • Tonkin A.M.
        • Lewis B.S.
        • Felix C.
        • Yusoff K.
        • Metsarinne K.P.
        • Fox K.A.A.
        • Yusuf S.
        Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin.
        Gastroenterology. 2019; https://doi.org/10.1053/j.gastro.2019.05.056
        • Bernaudo D.
        • Coll R.
        • Sanchez Munoz-Torrero J.F.
        • Pascual M.T.
        • Garcia-Diaz A.M.
        • Alvarez L.R.
        • Monreal M.
        Renal function and short-term outcome in stable outpatients with coronary, cerebrovascular or peripheral artery disease.
        Atherosclerosis. 2013; 229: 258-262https://doi.org/10.1016/j.atherosclerosis.2013.04.029
        • Barba R.
        • Bisbe J.
        • Pedrajas J.N.A.
        • Toril J.
        • Monte R.
        • Munoz-Torrero J.F.S.
        • Monreal M.
        Body mass index and outcome in patients with coronary, cerebrovascular, or peripheral artery disease: findings from the FRENA registry.
        Eur. J. Cardiovasc. Prev. Rehabil. 2009; 16: 457-463https://doi.org/10.1097/HJR.0b013e32832b1818
        • Garcia-Diaz A.M.
        • Marchena P.J.
        • Toril J.
        • Arnedo G.
        • Munoz-Torrero J.F.S.
        • Yeste M.
        • Aguilar E.
        • Monreal M.
        Alcohol consumption and outcome in stable outpatients with peripheral artery disease.
        J. Vasc. Surg. 2011; 54: 1081-1087https://doi.org/10.1016/j.jvs.2011.03.285
        • Perez P.
        • Esteban C.
        • Caballero P.E.J.
        • Munoz-Torrero J.F.S.
        • Soria M.T.P.
        • Aguilar E.
        • Rodriguez L.R.A.
        • Sahuquillo J.C.
        • Diaz A.M.G.
        • Monreal M.
        Anemia and outcome in outpatients with peripheral artery disease.
        Angiology. 2016; 67: 484-489https://doi.org/10.1177/0003319715599864
        • Alvarez L.R.
        • Balibrea J.M.
        • Surinach J.M.
        • Coll R.
        • Pascual M.T.
        • Toril J.
        • Lopez-Jimenez L.
        • Monreal M.
        Smoking cessation and outcome in stable outpatients with coronary, cerebrovascular, or peripheral artery disease.
        Eur. J. Prev. Cardiol. 2013; 20: 486-495https://doi.org/10.1177/1741826711426090
        • Camafort M.
        • Alvarez-Rodriguez L.R.
        • Munoz-Torrero J.F.S.
        • Sahuquillo J.C.
        • Lopez-Jimenez L.
        • Coll R.
        • Monreal M.
        Glucose control and outcome in patients with stable diabetes and previous coronary, cerebrovascular or peripheral artery disease. Findings from the FRENA registry.
        Diabet. Med. 2011; 28: 73-80https://doi.org/10.1111/j.1464-5491.2010.03153.x
        • Sanchez Munoz-Torrero J.F.
        • Rico-Martin S.
        • Alvarez L.R.
        • Aguilar E.
        • Alcala J.N.
        • Monreal M.
        Lipoprotein (a) levels and outcomes in stable outpatients with symptomatic artery disease.
        Atherosclerosis. 2018; 276: 10-14https://doi.org/10.1016/j.atherosclerosis.2018.07.001
        • Carson S.S.
        • Goss C.H.
        • Patel S.R.
        • Anzueto A.
        • Au D.H.
        • Elborn S.
        • Gerald J.K.
        • Gerald L.B.
        • Kahn J.M.
        • Malhotra A.
        • Mularski R.A.
        • Riekert K.A.
        • Rubenfeld G.D.
        • Weaver T.E.
        • Krishnan J.A.
        An official American Thoracic Society research statement: comparative effectiveness research in pulmonary, critical care, and sleep medicine.
        Am. J. Respir. Crit. Care Med. 2013; 188: 1253-1261https://doi.org/10.1164/rccm.201310-1790ST
        • Sun S.
        • Cui Z.
        • Zhou M.
        • Li R.
        • Li H.
        • Zhang S.
        • Ba Y.
        • Cheng G.
        Proton pump inhibitor monotherapy and the risk of cardiovascular events in patients with gastro-esophageal reflux disease: a meta-analysis.
        Neuro Gastroenterol. Motil. 2017; 29https://doi.org/10.1111/nmo.12926
        • Maggio M.
        • Corsonello A.
        • Ceda G.P.
        • Cattabiani C.
        • Lauretani F.
        • Butto V.
        • Ferrucci L.
        • Bandinelli S.
        • Abbatecola A.M.
        • Spazzafumo L.
        • Lattanzio F.
        Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals.
        JAMA Intern. Med. 2013; 173: 518-523https://doi.org/10.1001/jamainternmed.2013.2851
        • Xie Y.
        • Bowe B.
        • Li T.
        • Xian H.
        • Yan Y.
        • Al-Aly Z.
        Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans.
        BMJ Open. 2017; 7e015735https://doi.org/10.1136/bmjopen-2016-015735
        • Molina-Infante J.
        • Rivas M.D.
        • Hernandez-Alonso M.
        • Vinagre-Rodriguez G.
        • Mateos-Rodriguez J.M.
        • Duenas-Sadornil C.
        • Perez-Gallardo B.
        • Ferrando-Lamana L.
        • Fernandez-Gonzalez N.
        • Banares R.
        • Zamorano J.
        Proton pump inhibitor-responsive oesophageal eosinophilia correlates with downregulation of eotaxin-3 and Th2 cytokines overexpression.
        Aliment. Pharmacol. Ther. 2014; 40: 955-965https://doi.org/10.1111/apt.12914
        • Chanchal S.K.
        • Mahajan U.B.
        • Siddharth S.
        • Reddy N.
        • Goyal S.N.
        • Patil P.H.
        • Bommanahalli B.P.
        • Kundu C.N.
        • Patil C.R.
        • Ojha S.
        In vivo and in vitro protective effects of omeprazole against neuropathic pain.
        Sci. Rep. 2016; 6: 30007https://doi.org/10.1038/srep30007
        • Patil A.S.
        • Singh A.D.
        • Mahajan U.B.
        • Patil C.R.
        • Ojha S.
        • Goyal S.N.
        Protective effect of omeprazole and lansoprazole on beta-receptor stimulated myocardial infarction in Wistar rats.
        Mol. Cell. Biochem. 2019; 456: 105-113https://doi.org/10.1007/s11010-019-03494-y
        • Taleb S.
        Inflammation in atherosclerosis.
        Arch. Cardiovasc. Dis. 2016; 109: 708-715https://doi.org/10.1016/j.acvd.2016.04.002
        • Strand D.S.
        • Kim D.
        • Peura D.A.
        25 Years of proton pump inhibitors: a comprehensive review.
        Gut Liver. 2017; 11: 27-37https://doi.org/10.5009/gnl15502